BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, June 4, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 20, 2007
View Archived Issues
IPI-504 overcomes gefitinib resistance in non-small cell lung cancer cell lines
Read More
Velcade's significant efficacy advantage prompts early end of phase III clinical trial
Read More
FDA grants orphan drug designation to Infinity and MedImmune's IPI-504 for GIST
Read More
MicroIslet and Progenitor sign manufacturing agreement for MicroIslet-P
Read More
FDA approves five-day, once-daily regimen of Levaquin for cUTI and AP
Read More
University of Nottingham develops possible HCV vaccine
Read More
Provectus announces results of phase I metastatic melanoma study
Read More
Recent patents describe novel agents for psychiatric disorders
Read More
CP-3242: a novel metallo-beta-lactamase inhibitor profiled at the ICAAC meeting
Read More
Update on EpiCept's MAA for Ceplene in E.U.
Read More
Sosei completes phase II proof-of-principle trial of AD-337 for FMS
Read More
Novel therapeutic agents for thrombotic disorders reported in recent Trigen patent
Read More
Phase I/II clinical program to study Torisel/Velcade combination in multiple myeloma
Read More
FDA accepts Samaritan's IND for SP-6300 in Cushing's syndrome
Read More
Targeted Genetics reports results of RAC hearing on phase I/II trial of tgAAC94
Read More
Perseus and Brigham sign research agreement for cardiovascular risk predictor PTX3
Read More
MorphoSys initiates phase I trial of HuCAL gold-derived fully human antibody
Read More
Bristol-Myers begins phase II trial of p38 kinase inhibitor BMS-582949 for psoriasis
Read More
Aphios and Boston University awarded development grant for APH-M109
Read More
Phase I trial expanded after alvespimycin shows activity in metastatic breast cancer
Read More
Meta-analysis: Pioglitazone reduces ischemic cardiovascular risk in diabetes patients
Read More
mGlu2/3 receptor activation with LY-2140023 improves schizophrenia symptoms
Read More
Positive preclinical results of novel RSV fusion inhibitor TMC-353121
Read More
Triple beta-lactam combination effective in Gram-negative sepsis models
Read More
FDA grants Preos orphan drug status in hypoparathyroidism indication
Read More
E.U. grants Novo Nordisk approval for use of NovoRapid in elderly people
Read More
Smaller dose Tamiflu approved in Europe; expanded use of FluMist approved in U.S.
Read More
EMEA grants Progen's PI-88 orphan drug designation
Read More
